Thursday 20 September 2018 at 4:00 pm in QCRI 100/01 Conf. Rms.
F. Chris MacPhee Assistant Director (Operations) Centre for Advance Computing @ Queen's
Title: "Secret Identity: CAC, PHI, and You"
Do you have a family doctor in Canada? Have you received medical treatment in Ontario? Do you enjoy going to the movies? If you answered yes to any of the previous questions, your secret identity (aka PHI and PI) already resides at the CAC!
The Centre for Advanced Computing (CAC) @ Queen’s University is your local research IT solution provider. As a university centre, we are mandated to help in the design, implementation, and support of secure, advanced computing solutions for academic and medical clients. A security and privacy focus at CAC enables our partners to meet the strictest regulatory frameworks and standards in Canada and worldwide, facilitating residency of health data from dozens of different hospitals and clinics across in Canada.
We look forward to sharing some great opportunities and resources available to the Queen’s community. Note that capes, masks, and tights not required for the seminar, but are encouraged.
Host: Dr. Lois Mulligan (email@example.com; ext 77475)
Monday 15 October 2018 at 4:00 pm in QCRI 100/01 Conf Rms.
Tricia Cottrell, MD, PhD Chief Resident, Anatomic Pathology (PGY4) Johns Hopkins University School of Medicine (Baltimore, MD)
"Histopathologic features of response and resistance to neoadjuvant anti-PD-1 in non-small cell lung carcinoma (NSCLC)"
Features of the pretreatment tumor microenvironment (TME) are broadly associated with patient prognosis and useful in enriching for subsets of patients likely to respond to immune checkpoint blockade. In the neoadjuvant setting, the post-treatment TME provides an early indicator of a particular patient’s response status and allows investigation of mechanisms underlying primary resistance. We systematically identified the histopathologic features of immune-mediate tumor regression following neoadjuvant anti-PD1 in NSCLC. These features were used to develop a reproducible method for quantifying pathologic response in this setting, known as 'Immune-Related Pathologic Response Criteria' (irPRC). Early data suggests that these criteria may also be useful in other tumor types, possibly representing a pan-cancer tool for pathologic response assessment. Finally, we are using an optimized and validated multiplex immunofluorescence protocol to explore both pretreatment and post treatment tumor specimens to improve predictions of therapeutic response and identify mechanisms of resistance to immune checkpoint blockade.